Background and objective: Opioid maintenance treatment (OMT) is highly available in Norway, but only 50% of opioid-dependent individuals are enrolled in such programs. This study was aimed at examining if availability of extended-release naltrexone (XR-NTX) could attract individuals who for different reasons were not enrolled in an OMT program. Methods: In a Norwegian clinical study, n = 117 opioid-dependent adults volunteered to receive XR-NTX in a 9-month period, as an extension of a previous randomized clinical trial. Results: Before study inclusion, 40.2% (n = 47) of the study participants were not enrolled in OMT while the remainder were recruited from OMT. Participants not enrolled in OMT displayed more ongoing severe addiction-related problems such as heroin use (p = 0.002), but displayed a higher retention in treatment in the 9-month extension study (p = 0.048 for log-rank test) than participants enrolled in OMT. Conclusion: Availability of XR-NTX attracted opioid-dependent individuals not previously enrolled in OMT. While OMT may be perceived as a burden with regard to daily intake and control measures, one-monthly injections with XR-NTX may be perceived favourable, offering more freedom to the patients, not having addictive properties, and potentially reducing heroin craving. We suggest that an introduction of XR-NTX in Europe may increase the number of opioid-dependent individuals in treatment.

Keywords:
Naltrexone, Extended-release naltrexone, Opioid dependency, Maintenance treatment program, Treatment of opioid dependence, Opioid maintenance treatment
1.
Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.
Addiction
. 2011 Jan;106(1):32–51.
2.
Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic.
N Engl J Med
. 2014 May;370(22):2063–6.
3.
WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Denpendence, 2009. Available from: http://www.who.int/substance_abuse/activities/treatment_opioid_dependence/en/: World Health Organization.
4.
Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.
Harv Rev Psychiatry
. 2015 Mar-Apr;23(2):63–75.
5.
Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Cochrane Database Syst Rev
. 2014 Feb;(2):CD002207.
6.
Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study.
Drug Alcohol Depend
. 2008 Apr;94(1–3):151–7.
7.
Bukten A, Røislien J, Skurtveit S, Waal H, Gossop M, Clausen T. A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study.
BMC Psychiatry
. 2013 Oct;13(1):262.
8.
Bart G. Maintenance medication for opiate addiction: the foundation of recovery.
J Addict Dis
. 2012;31(3):207–25.
9.
Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen HU. Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample.
Eur Addict Res
. 2017;23(2):97–105.
10.
Waal H, Bussesund K, Clausen T, Skeie I, Håseth A, Lillevold P. The annual OMT status survey for 2014 (In Norwegian only: Statusrapport 2014-En aldrende LAR-populasjon). Norwegian Centre for Addiction Research; 2015.
11.
EMCDDA. European Drug Report: Trend and Developments. Available from: http://www.emcdda.europa.eu/publications/edr/trends-developments/2015: European Monitoring Centre for Drugs and Drug Addiction; 2015.
12.
Gastfriend DR. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
Ann N Y Acad Sci
. 2014 Oct;1327:112–30.
13.
Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Addiction
. 2013 Sep;108(9):1628–37.
14.
Sideroff SI, Charuvastra VC, Jarvik ME, Ouren J. Craving in heroin addicts maintained on the opiate antagonist naltrexone.
Am J Drug Alcohol Abuse
. 1978;5(4):415–23.
15.
Sullivan MA, Bisaga A, Mariani JJ, Glass A, Levin FR, Comer SD, et al. Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?
Drug Alcohol Depend
. 2013 Nov;133(1):80–5.
16.
Herbeck DM, Jeter KE, Cousins SJ, Abdelmaksoud R, Crèvecoeur-MacPhail D. Gender differences in treatment and clinical characteristics among patients receiving extended release naltrexone.
J Addict Dis
. 2016 Oct-Dec;35(4):305–14.
17.
Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man.
Arch Gen Psychiatry
. 1973 Jun;28(6):784–91.
18.
Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained-release preparation.
Drug Alcohol Depend
. 1985 Sep;16(1):1–8.
19.
Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.
Br J Psychiatry
. 2009 Jun;194(6):541–6.
20.
Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al.; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
JAMA
. 2005 Apr;293(13):1617–25.
21.
Gastfriend DR. Intramuscular extended-release naltrexone: current evidence.
Ann N Y Acad Sci
. 2011 Jan;1216(1):144–66.
22.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.
Arch Gen Psychiatry
. 2006 Feb;63(2):210–8.
23.
Hulse GK, Morris N, Arnold-Reed D, Tait RJ. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
Arch Gen Psychiatry
. 2009 Oct;66(10):1108–15.
24.
Digiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
Addiction
. 2004 Apr;99(4):450–60.
25.
Kunøe N, Lobmaier P, Ngo H, Hulse G. Injectable and implantable sustained release naltrexone in the treatment of opioid addiction.
Br J Clin Pharmacol
. 2014 Feb;77(2):264–71.
26.
Vanderplasschen W, Naert J, Vander Laenen F, De Maeyer J. Treatment satisfaction and quality of support in outpatient substitution treatment: opiate users’ experiences and perspectives.
Drugs Educ Prev Policy
. 2015;22(3):272–80.
27.
Harris J, McElrath K. Methadone as social control: institutionalized stigma and the prospect of recovery.
Qual Health Res
. 2012 Jun;22(6):810–24.
28.
Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
JAMA Psychiatry
. 2017 Dec;74(12):1197–205.
29.
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lancet
. 2018 Jan;391(10118):309–18.
30.
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Lancet
. 2011 Apr;377(9776):1506–13.
31.
Aletraris L, Bond Edmond M, Roman PM. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
J Stud Alcohol Drugs
. 2015 Jan;76(1):143–51.
32.
Sharma Haase K, Kunøe N, Opheim A, Gaulen Z, Njå AM, Latif ZE, et al. Interest in Extended Release Naltrexone among Opioid Users.
Eur Addict Res
. 2016;22(6):301–5.
33.
Zaaijer ER, Goudriaan AE, Koeter MW, Booij J, van den Brink W. Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands.
Subst Use Misuse
. 2016 Dec;51(14):1905–11.
34.
Solli KK, Latif ZE, Opheim A, Krajci P, Sharma-Haase K, Benth JŠ, et al. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
Addiction
. 2018 Oct;113(10):1840–9.
35.
Waal H, Bussesund K, Clausen T, Skeie I, Håseth A, Lillevold P. The annual OMT status survey for 2015.
Norwegian only: Statusrapport 2015-Mot grensene for vekst og nytte?
Norwegian Centre for Addiction Research; 2016.
36.
Kunøe N, Opheim A, Solli KK, Gaulen Z, Sharma-Haase K, Latif ZE, et al. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
BMC Pharmacol Toxicol
. 2016 Apr;17(1):18.
37.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33.
38.
Kokkevi A, Hartgers C. EuropASI: European Adaptation of a Multidimensional Assessment Instrument for Drug and Alcohol Dependence.
Eur Addict Res
. 1995;1(4):208–10.
39.
Indergård PJ, Solbakken T, Urfjell B. Activity data for mental health services for adults and specialized substance abuse treatment 2014 (In Norwegian only: Aktivitetsdata for psykisk helsevern for voksne og tverrfaglig spesialisert rusbehandling 2014); 2014.
40.
Cousins SJ, Radfar SR, Crèvecoeur-MacPhail D, Ang A, Darfler K, Rawson RA. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
J Subst Abuse Treat
. 2016 Apr;63:66–71.
41.
Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.
Drug Alcohol Rev
. 2017 May;36(3):305–10.
42.
Deering DE, Sheridan J, Sellman JD, Adamson SJ, Pooley S, Robertson R, et al. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness.
Addict Behav
. 2011 Jun;36(6):636–42.
43.
Lugoboni F, Zamboni L, Cibin M, Tamburin S; Gruppo InterSERT di Collaborazione Scientifica (GICS). Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
Eur Addict Res
. 2019;25(1):10–9.
44.
Neale J, Nettleton S, Pickering L. What is the role of harm reduction when drug users say they want abstinence?
Int J Drug Policy
. 2011 May;22(3):189–93.
45.
Notley C, Blyth A, Maskrey V, Craig J, Holland R. The experience of long-term opiate maintenance treatment and reported barriers to recovery: a qualitative systematic review.
Eur Addict Res
. 2013;19(6):287–98.
46.
Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored.
Mt Sinai J Med
. 2001 Jan;68(1):62–74.
47.
Henriksen K, Jacobsen JA, Henriksen EM, Gomes L, Waal H, Krajci P. The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting.
Eur Addict Res
. 2018;24(6):286–92.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.